Hims & Hers: Post Earnings Drop Is Very Welcomed
Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted EBITDA increased 163% YoY, highlighting long-term growth potential. Management's goal of 10 million subscribers in 5–6 years, with AI integration and Trybe Labs acquisition, presents a bullish opportunity.
Compared to Estimates, Hims & Hers Health (HIMS) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Hims & Hers Health (HIMS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Markets Mostly Dip Red Late in Regular Trading
After the closing bell, Zoom shares are -4% and HIMS are trading -17% lower on Q4 earnings results.
Hims & Hers Health, Inc. (HIMS) Lags Q4 Earnings Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.01 per share a year ago.
Hims & Hers Shares Plunge as Costs Tied to Weight-Loss Drugs Squeeze Margins
Shares of Hims & Hers Health (HIMS) shares plunged in late trading Monday after the company reported falling margins as costs rose, overshadowing better-than-expected sales.
Hims & Hers shares tumble over concerns around weight-loss business
The 'Fast Money' traders talk Hims & Hers shares falling despite beat as concerns around weight-loss business escalate.
Hims & Hers warns its supply of compounded weight loss drugs could be 'constrained'
Hims & Hers said the U.S. FDA's decision that the shortage of Novo Nordisk's weight-loss and diabetes drugs had been resolved could constrain the telehealth firm's ability to continue providing access to compounded versions of the drugs on its platform once current inventory has been sold.
Hims & Hers offers upbeat forecast, but stock slides after hours
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street's expectations, but shares fell hard in after-hours trading, in an echo of Friday's sell-off amid concerns about the fate of its Ozempic alternatives.
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was over.
Here's Why Hims & Hers Health, Inc. (HIMS) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Options Corner: HIMS Earnings Ahead
Hims & Hers Health (HIMS) had a volatile trading week ending with both a new 52-week high and a 18% drop. Rick Ducat examines the technical levels to track as investors prepare for the company's 4Q earnings report.
Overlooked Stock: HIMS
Hims & Hers Health (HIMS) sold off most of its massive rally today that it got over the last couple weeks. George Tsilis points out that the FDA no longer sees shortages of Novo Nordisk's (NVO) Ozempic and Wegovy weight loss drugs.
